Document is current
Any future updates will be listed below
-
Authors
Hund, Inga
Hess, Maria Elena https://orcid.org/0009-0007-5792-3657
Andrieux, Geoffroy https://orcid.org/0000-0002-5389-9481
Stomper, Julia https://orcid.org/0000-0002-3858-4385
Greve, Gabriele
Niemöller, Christoph
Ma, Tobias https://orcid.org/0009-0009-1258-8976
Uhl, David
Grishina, Olga
Thol, Felicitas https://orcid.org/0000-0001-5848-6152
Heuser, Michael https://orcid.org/0000-0001-5318-9044
Bug, Gesine https://orcid.org/0000-0003-2359-131X
Crysandt, Martina
Neubauer, Andreas https://orcid.org/0000-0002-7606-8760
Duyster, Justus https://orcid.org/0000-0001-7325-7753
Döhner, Hartmut https://orcid.org/0000-0003-2116-5536
Boerries, Melanie https://orcid.org/0000-0002-3670-0602
Lübbert, Michael https://orcid.org/0000-0003-1186-1650
Becker, Heiko https://orcid.org/0000-0002-6919-4048
-
Funding
Funding for this research was provided by:
Deutsche Forschungsgemeinschaft (FOR 2674 A05 BE 6461/1-2, FOR 2674 A02, LU 429/16-2)
Bundesministerium für Bildung und Forschung (NanodiagBW P3, EkoEstMed–FKZ 01ZZ2015, PM4Onco–FKZ 01ZZ2322A)
José Carreras Leukämie-Stiftung (17 R/2019, AH06-01)
- License Information
-
More Information
Article History
Received: 8 June 2025
Revised: 22 August 2025
Accepted: 23 September 2025
First Online: 7 October 2025
Competing interests
: HB: honoraria from AbbVie, Bristol Myers Squibb, GlaxoSmithKline, Lilly, Merck Sharp & Dohme, Novartis, Pierre Fabre Pharma, and Servier. HD: consultancy (AdBoard) with honoraria for AbbVie, Otsuka, Pfizer, Servier, Syndax; and clinical research funding to the institution from AbbVie, Astellas, Bristol Myers Squibb, Jazz Pharmaceuticals, Servier; and travel/ accommodation expenses from AbbVie, Servier. The remaining authors declare that they have no competing interests.
: All study methods were performed in accordance with relevant guidelines and regulations. Ethics approval was obtained from the Ethics Committee at the University of Freiburg (76/10-120689). Written informed consent was obtained from all subjects.
